Abbonarsi

The MBOAT7 rs641738 variant is associated with an improved outcome in primary sclerosing cholangitis - 11/10/20

Doi : 10.1016/j.clinre.2019.12.006 
Cora Freund a , Arne Wahlers a , Nima Haji Begli a , Yvonne Leopold a , Petra Klöters-Plachky a , Arianeb Mehrabi b , Isabelle Mohr a , Julia Sander a , Christian Rupp a , Daniel Nils Gotthardt a, c , Karl Heinz Weiss a,
a Department of Internal Medicine IV, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany 
b Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany 
c Mediteo GmbH, Hauptstraße 90, 69117 Heidelberg, Germany 

Corresponding author.

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

pagine 7
Iconografia 5
Video 0
Altro 0

Highlights

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease that causes liver cirrhosis, leading to liver failure.
The sole curative option for PSC to date is liver transplantation.
The membrane bound O-acyltransferase domain containing 7 (MBOAT7) rs641738 and rs626283 variant alleles have been associated with both an accelerated progression of the disease and a higher risk for developing a more severe phenotype in many chronic hepatic diseases.
Thus, we analysed their effect on long-term outcomes in PSC patients.
We found that transplant-free survival was significantly prolonged – not reduced – in carriers of two rs641738 variant alleles, which was referred to as the TT genotype (mean 19.6 years; 95% confidence interval [CI]: 16.3–22.9 years) compared to the CC (mean 15.4 years, 95% CI 12.8–18.0 years) and heterozygous genotypes (mean 13.2 years, 95% CI 11.4–15.0 years) (P=0.017).
This study could help improve individual prognosis in PSC patients and give some new perspective on the involvement of the immune system in PSC.

Il testo completo di questo articolo è disponibile in PDF.

Summary

Background and aims

Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease that causes liver cirrhosis, leading to liver failure. Additionally, PSC is a risk factor for cholangiocarcinoma. Its mechanism is unknown, and liver transplantation remains the sole curative option. The membrane bound O-acyltransferase domain containing 7 (MBOAT7) rs641738 and rs626283 variant alleles have been associated with both an accelerated progression of the disease and a higher risk for developing a more severe phenotype in many chronic hepatic diseases. Thus, we analysed their effect on long-term outcomes and laboratory parameters in PSC patients.

Methods

We determined MBOAT7 genotypes and estimated the actuarial survival rate free of liver transplantation, using the Kaplan-Meier estimator. The differences between the estimates were analysed using the log-rank test. Patient blood was drawn and analysed for different serum parameters including cholestatic markers. Additionally, MBOAT7 RNA expression in human hepatic cell lines MZCHA1 (a biliary adenocarcinoma cell line), HepG2 (a hepatocellular carcinoma cell line), LX-2 (hepatic stellate cell line) and H-69 (cholangiocyte cell line) was analysed.

Results

Transplant-free survival was significantly prolonged in carriers of two rs641738 variant alleles, which was referred to as the TT genotype (mean 19.6 years; 95% confidence interval [CI]: 16.3–22.9 years) compared to the CC (mean 15.4 years, 95% CI 12.8–18.0 years) and heterozygous genotypes (mean 13.2 years, 95% CI 11.4–15.0 years) (P=0.017). This effect was restricted to male patients. We confirmed the high expression of MBOAT7 in hepatic stellate cells and found that MBOAT7 is less expressed in biliary epithelial cell lines, compared to parenchymal hepatic cells.

Conclusions

Unlike other chronic liver diseases, carrying two MBOAT7 variant alleles does not seem to affect PSC patients negatively, but seems to have a positive effect on transplant-free survival. This study could help improve individual prognosis in PSC patients and give some new perspective on the involvement of the immune system in PSC.

Il testo completo di questo articolo è disponibile in PDF.

Keywords : Primary sclerosing cholangitis, Membrane bound O-acyltransferase domain containing 7 gene, Hepatic fibrosis, Hepatic stellate cells

Abbreviations : PSC, MBOAT7, NAFLD


Mappa


© 2019  Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 44 - N° 5

P. 646-652 - Ottobre 2020 Ritorno al numero
Articolo precedente Articolo precedente
  • Surgical management of oligometastatic disease in gastric cancer
  • Peng Jin, Xiaoyan Ji, Yantao Tian
| Articolo seguente Articolo seguente
  • The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis
  • Haizhou Wang, Peishan Qiu, Jing Liu, Fan Wang, Qiu Zhao

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.